The University of Utah has been awarded a $1,837,542 Cooperative Agreement from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The project, titled "Targeting Treatment-Resistant OUD with Ketamine-Assisted Mindfulness-Oriented Recovery Enhancement," aims to investigate the safety, efficacy, and mechanisms of a combination therapy using ketamine and mindfulness-oriented recovery enhancement (MORE) for patients with treatment-resistant opioid use disorder (OUD) receiving buprenorphine. The study will first conduct a Phase 2 placebo-controlled randomized clinical trial, and if successful, will proceed to a Phase 3 trial in community-based clinics. The research seeks to determine if the MORE + ketamine intervention can reduce drug use, improve treatment adherence, and enhance outcomes for this patient population compared to a MORE + placebo condition. The project will also examine the psychological and neurophysiological mechanisms underlying the potential benefits of this novel OUD treatment approach.
Generated 3/4/25, 7:18 AM